Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Michael Walter

Michael Walter
Managing Editor


Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

LATEST ARTICLES BY THIS AUTHOR

Abbott executive who led TAVR, Tendyne divisions announces exit
Heavy cannabis use may not impact heart surgery outcomes
Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs
Minnesota medtech companies call for ‘de-escalation’ after Alex Pretti’s death
Medtronic’s newest all-in-one PFA catheter gains critical approval
Vascular surgeon accused of double murder pleads not guilty
Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech
Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices
FDA-approved PFA system linked to positive 1-year data, ‘impeccable’ durability
Johnson & Johnson CEO celebrates company’s cardiovascular business during Q4 earnings call

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …42
    • Page 43
    • Page 44
    • Page 45
    • Current page 46
    • Page 47
    • Page 48
    • Page 49
    • Page 50 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme